BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22

  • The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's BMRN marketing application seeking approval for hemophilia A gene therapy, valoctocogene roxaparvovec.
  • With today's validation, the application review can now commence. A CHMP opinion is anticipated in the first half of 2022.
  • BioMarin resubmitted the European marketing application in June.
  • In the U.S., BioMarin intends to submit two-year follow-up safety and efficacy data on all study participants from the Phase 3 GENEr8-1 study to support the benefit/risk assessment of valoctocogene roxaparvovec, as previously requested by the FDA.
  • BioMarin targets an application resubmission in Q2 of 2022, assuming favorable study results, followed by an expected six-month review by the FDA.
  • Price Action: BMRN shares are down 1.21% at $78.72 during the market session on the last check Thursday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsgene therapyHemophilia A
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!